Cargando…
Cure in metastatic breast cancer
Oligometastatic disease characterizes a distinct subgroup of metastatic breast cancer patients that might benefit from different treatment strategies to achieve long-lasting remission and potentially cure. Those long-lasting remissions are reported after locoregional treatment of the primary tumor a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132799/ https://www.ncbi.nlm.nih.gov/pubmed/30220923 http://dx.doi.org/10.1007/s12254-018-0426-9 |
_version_ | 1783354388651180032 |
---|---|
author | Westphal, Theresa Gampenrieder, Simon Peter Rinnerthaler, Gabriel Greil, Richard |
author_facet | Westphal, Theresa Gampenrieder, Simon Peter Rinnerthaler, Gabriel Greil, Richard |
author_sort | Westphal, Theresa |
collection | PubMed |
description | Oligometastatic disease characterizes a distinct subgroup of metastatic breast cancer patients that might benefit from different treatment strategies to achieve long-lasting remission and potentially cure. Those long-lasting remissions are reported after locoregional treatment of the primary tumor and all metastatic sites in several case series; however, unlike other tumor entities, prospective data are lacking. Furthermore, tumor eradication by excellent systemic anticancer therapy with novel chemotherapies and targeted agents can lead to long-term survival. In addition, reactivation of the host immune defense by immuno-oncologic drugs can achieve long-lasting tumor control. So far, unfortunately, checkpoint inhibitors as monotherapy have led to responses only in a small percentage of patients with metastatic breast cancer. This short review summarizes available data on long-lasting remissions and potential cure in metastatic breast cancers. It describes and discusses data on locoregional treatment, chemo-, antibody- and immunotherapy and tries to select individual patients for whom a multidisciplinary treatment approach with curative intention might be an option to achieve long-term survival. |
format | Online Article Text |
id | pubmed-6132799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-61327992018-09-13 Cure in metastatic breast cancer Westphal, Theresa Gampenrieder, Simon Peter Rinnerthaler, Gabriel Greil, Richard Memo Short Review Oligometastatic disease characterizes a distinct subgroup of metastatic breast cancer patients that might benefit from different treatment strategies to achieve long-lasting remission and potentially cure. Those long-lasting remissions are reported after locoregional treatment of the primary tumor and all metastatic sites in several case series; however, unlike other tumor entities, prospective data are lacking. Furthermore, tumor eradication by excellent systemic anticancer therapy with novel chemotherapies and targeted agents can lead to long-term survival. In addition, reactivation of the host immune defense by immuno-oncologic drugs can achieve long-lasting tumor control. So far, unfortunately, checkpoint inhibitors as monotherapy have led to responses only in a small percentage of patients with metastatic breast cancer. This short review summarizes available data on long-lasting remissions and potential cure in metastatic breast cancers. It describes and discusses data on locoregional treatment, chemo-, antibody- and immunotherapy and tries to select individual patients for whom a multidisciplinary treatment approach with curative intention might be an option to achieve long-term survival. Springer Vienna 2018-08-17 2018 /pmc/articles/PMC6132799/ /pubmed/30220923 http://dx.doi.org/10.1007/s12254-018-0426-9 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Short Review Westphal, Theresa Gampenrieder, Simon Peter Rinnerthaler, Gabriel Greil, Richard Cure in metastatic breast cancer |
title | Cure in metastatic breast cancer |
title_full | Cure in metastatic breast cancer |
title_fullStr | Cure in metastatic breast cancer |
title_full_unstemmed | Cure in metastatic breast cancer |
title_short | Cure in metastatic breast cancer |
title_sort | cure in metastatic breast cancer |
topic | Short Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132799/ https://www.ncbi.nlm.nih.gov/pubmed/30220923 http://dx.doi.org/10.1007/s12254-018-0426-9 |
work_keys_str_mv | AT westphaltheresa cureinmetastaticbreastcancer AT gampenriedersimonpeter cureinmetastaticbreastcancer AT rinnerthalergabriel cureinmetastaticbreastcancer AT greilrichard cureinmetastaticbreastcancer |